Mutation Profiling in Cholangiocarcinoma

Discussion Board › Forums › General Discussion › Mutation Profiling in Cholangiocarcinoma

Viewing 3 posts - 1 through 3 (of 3 total)
  • Author
    Posts
  • October 17, 2016 at 11:51 pm #17262
    marions
    Moderator

    Thanks for that, dear Gavin.

    October 17, 2016 at 9:07 pm #17263
    gavin
    Moderator

    Thanks for that Marion. Here is the link that you posted, hope this one works.

    http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0115383

    October 17, 2016 at 7:23 pm #764
    marions
    Moderator

    What are the Prognostic and Therapeutic Implication?

    The 46 genes in the panel for detection of targetable mutations included: AKT1, BRAF, FGFR1, GNAS, IDH1, FGFR2, KRAS, NRAS, PIK3CA, MET, RET, EGFR, JAK2, MPL, PDGFRA, PTEN, TP53, FGFR3, FLT3, KIT, ERBB2, ABL1, HNF1A, HRAS, ATM, RB1, CDH1, SMAD4, STK11, ALK, SRC, SMARCB1, VHL, MLH1, CTNNB1, KDR, FBXW7, APC, CSF1R, NPM1, SMO, ERBB4, CDKN2A, NOTCH1, JAK3, and PTPN11

    There are significant genetic differences between intra and extrahepatic CCA.

    IDH1 and DNA repair gene alterations occurred more frequently in intrahepatic CCA
    as well as TP53 (35%), KRAS (24%), ARID1A (20%), IDH1 (18%), MCL1 (16%) and PBRM1 (11%).

    extrahepatic group had higher occurrence of ERBB2 genomic alterations
    as well as TP53 (45%), KRAS (40%), ERBB2 (25%), SMAD4 (25%), FBXW7 (15%) and CDKN2A (15%)

    read more:http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0115383

  • Author
    Posts
Viewing 3 posts - 1 through 3 (of 3 total)
  • The forum ‘General Discussion’ is closed to new topics and replies.